Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 123

Published Date: 02 Sep 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.

Small nucleic acid drugs are short in length and have a base of less than 30 nt. They mainly act on mRNA in cells through the principle of complementary base pairing to regulate protein expression, thereby achieving therapeutic effects. It can be further divided into single-stranded antisense oligonucleotide ASO, and double-stranded nucleotide siRNA.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Antisense oligonucleotides (ASO) Drug and siRNA Drug industry chain, the market status of Single Gene Rare Disease (Antisense Oligonucleotides (ASO) Drug, siRNA Drug), Protein Deposition Disease (Antisense Oligonucleotides (ASO) Drug, siRNA Drug), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Antisense oligonucleotides (ASO) Drug and siRNA Drug.

Regionally, the report analyzes the Antisense oligonucleotides (ASO) Drug and siRNA Drug markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the Antisense oligonucleotides (ASO) Drug and siRNA Drug market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Antisense oligonucleotides (ASO) Drug and siRNA Drug industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Antisense Oligonucleotides (ASO) Drug, siRNA Drug).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Antisense oligonucleotides (ASO) Drug and siRNA Drug market.

Regional Analysis: The report involves examining the Antisense oligonucleotides (ASO) Drug and siRNA Drug market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Antisense oligonucleotides (ASO) Drug and siRNA Drug market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Antisense oligonucleotides (ASO) Drug and siRNA Drug:
Company Analysis: Report covers individual Antisense oligonucleotides (ASO) Drug and siRNA Drug manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Antisense oligonucleotides (ASO) Drug and siRNA Drug This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Single Gene Rare Disease, Protein Deposition Disease).

Technology Analysis: Report covers specific technologies relevant to Antisense oligonucleotides (ASO) Drug and siRNA Drug. It assesses the current state, advancements, and potential future developments in Antisense oligonucleotides (ASO) Drug and siRNA Drug areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Antisense oligonucleotides (ASO) Drug and siRNA Drug market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
Antisense oligonucleotides (ASO) Drug and siRNA Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Antisense Oligonucleotides (ASO) Drug
siRNA Drug

Market segment by Application
Single Gene Rare Disease
Protein Deposition Disease
Chronic Liver Disease
Others

Major players covered
Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure
Secarna
AstraZeneca
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
Miragen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antisense oligonucleotides (ASO) Drug and siRNA Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug, with price, sales, revenue and global market share of Antisense oligonucleotides (ASO) Drug and siRNA Drug from 2018 to 2023.
Chapter 3, the Antisense oligonucleotides (ASO) Drug and siRNA Drug competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antisense oligonucleotides (ASO) Drug and siRNA Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Antisense oligonucleotides (ASO) Drug and siRNA Drug market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antisense oligonucleotides (ASO) Drug and siRNA Drug.
Chapter 14 and 15, to describe Antisense oligonucleotides (ASO) Drug and siRNA Drug sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Antisense oligonucleotides (ASO) Drug and siRNA Drug
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Antisense Oligonucleotides (ASO) Drug
        1.3.3 siRNA Drug
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Single Gene Rare Disease
        1.4.3 Protein Deposition Disease
        1.4.4 Chronic Liver Disease
        1.4.5 Others
    1.5 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size & Forecast
        1.5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (2018-2029)
        1.5.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 Alnylam
        2.1.1 Alnylam Details
        2.1.2 Alnylam Major Business
        2.1.3 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.1.4 Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Alnylam Recent Developments/Updates
    2.2 Ionis
        2.2.1 Ionis Details
        2.2.2 Ionis Major Business
        2.2.3 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.2.4 Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Ionis Recent Developments/Updates
    2.3 Biogen
        2.3.1 Biogen Details
        2.3.2 Biogen Major Business
        2.3.3 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.3.4 Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Biogen Recent Developments/Updates
    2.4 Novartis
        2.4.1 Novartis Details
        2.4.2 Novartis Major Business
        2.4.3 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.4.4 Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Novartis Recent Developments/Updates
    2.5 Sarepta Therapeutics
        2.5.1 Sarepta Therapeutics Details
        2.5.2 Sarepta Therapeutics Major Business
        2.5.3 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.5.4 Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Sarepta Therapeutics Recent Developments/Updates
    2.6 Therapeutics
        2.6.1 Therapeutics Details
        2.6.2 Therapeutics Major Business
        2.6.3 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.6.4 Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Therapeutics Recent Developments/Updates
    2.7 Akcea
        2.7.1 Akcea Details
        2.7.2 Akcea Major Business
        2.7.3 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.7.4 Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Akcea Recent Developments/Updates
    2.8 WAVElife
        2.8.1 WAVElife Details
        2.8.2 WAVElife Major Business
        2.8.3 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.8.4 WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 WAVElife Recent Developments/Updates
    2.9 ProQR
        2.9.1 ProQR Details
        2.9.2 ProQR Major Business
        2.9.3 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.9.4 ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 ProQR Recent Developments/Updates
    2.10 Exicure
        2.10.1 Exicure Details
        2.10.2 Exicure Major Business
        2.10.3 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.10.4 Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Exicure Recent Developments/Updates
    2.11 Secarna
        2.11.1 Secarna Details
        2.11.2 Secarna Major Business
        2.11.3 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.11.4 Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.11.5 Secarna Recent Developments/Updates
    2.12 AstraZeneca
        2.12.1 AstraZeneca Details
        2.12.2 AstraZeneca Major Business
        2.12.3 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.12.4 AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.12.5 AstraZeneca Recent Developments/Updates
    2.13 The WhiteOak Group, Inc.
        2.13.1 The WhiteOak Group, Inc. Details
        2.13.2 The WhiteOak Group, Inc. Major Business
        2.13.3 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.13.4 The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.13.5 The WhiteOak Group, Inc. Recent Developments/Updates
    2.14 Dicerna
        2.14.1 Dicerna Details
        2.14.2 Dicerna Major Business
        2.14.3 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.14.4 Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.14.5 Dicerna Recent Developments/Updates
    2.15 Silence
        2.15.1 Silence Details
        2.15.2 Silence Major Business
        2.15.3 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.15.4 Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.15.5 Silence Recent Developments/Updates
    2.16 Arrowhead
        2.16.1 Arrowhead Details
        2.16.2 Arrowhead Major Business
        2.16.3 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.16.4 Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.16.5 Arrowhead Recent Developments/Updates
    2.17 Miragen Therapeutics
        2.17.1 Miragen Therapeutics Details
        2.17.2 Miragen Therapeutics Major Business
        2.17.3 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.17.4 Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.17.5 Miragen Therapeutics Recent Developments/Updates
    2.18 Genzyme
        2.18.1 Genzyme Details
        2.18.2 Genzyme Major Business
        2.18.3 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.18.4 Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.18.5 Genzyme Recent Developments/Updates
    2.19 Quark Pharmaceuticals
        2.19.1 Quark Pharmaceuticals Details
        2.19.2 Quark Pharmaceuticals Major Business
        2.19.3 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.19.4 Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.19.5 Quark Pharmaceuticals Recent Developments/Updates
    2.20 Sylentis
        2.20.1 Sylentis Details
        2.20.2 Sylentis Major Business
        2.20.3 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.20.4 Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.20.5 Sylentis Recent Developments/Updates
    2.21 Avidity Biosciences
        2.21.1 Avidity Biosciences Details
        2.21.2 Avidity Biosciences Major Business
        2.21.3 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
        2.21.4 Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.21.5 Avidity Biosciences Recent Developments/Updates

3 Competitive Environment: Antisense oligonucleotides (ASO) Drug and siRNA Drug by Manufacturer
    3.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Manufacturer (2018-2023)
    3.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturer Market Share in 2022
        3.4.2 Top 6 Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturer Market Share in 2022
    3.5 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Overall Company Footprint Analysis
        3.5.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Region Footprint
        3.5.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Company Product Type Footprint
        3.5.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
        4.1.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2018-2029)
        4.1.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2018-2029)
        4.1.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Region (2018-2029)
    4.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029)
    4.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029)
    4.4 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029)
    4.5 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029)
    4.6 Middle East and Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2029)
    5.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Type (2018-2029)
    5.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2029)
    6.2 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Application (2018-2029)
    6.3 Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Application (2018-2029)

7 North America
    7.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2029)
    7.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2029)
    7.3 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
        7.3.1 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2029)
        7.3.2 North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2029)
    8.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2029)
    8.3 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
        8.3.1 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2029)
        8.3.2 Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Region
        9.3.1 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2029)
    10.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2029)
    10.3 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
        10.3.1 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2029)
        10.3.2 South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Size by Country
        11.3.1 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
    12.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
    12.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Antisense oligonucleotides (ASO) Drug and siRNA Drug and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Antisense oligonucleotides (ASO) Drug and siRNA Drug
    13.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Process
    13.4 Antisense oligonucleotides (ASO) Drug and siRNA Drug Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Antisense oligonucleotides (ASO) Drug and siRNA Drug Typical Distributors
    14.3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Alnylam Basic Information, Manufacturing Base and Competitors
    Table 4. Alnylam Major Business
    Table 5. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 6. Alnylam Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. Alnylam Recent Developments/Updates
    Table 8. Ionis Basic Information, Manufacturing Base and Competitors
    Table 9. Ionis Major Business
    Table 10. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 11. Ionis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. Ionis Recent Developments/Updates
    Table 13. Biogen Basic Information, Manufacturing Base and Competitors
    Table 14. Biogen Major Business
    Table 15. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 16. Biogen Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. Biogen Recent Developments/Updates
    Table 18. Novartis Basic Information, Manufacturing Base and Competitors
    Table 19. Novartis Major Business
    Table 20. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 21. Novartis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. Novartis Recent Developments/Updates
    Table 23. Sarepta Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 24. Sarepta Therapeutics Major Business
    Table 25. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 26. Sarepta Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Sarepta Therapeutics Recent Developments/Updates
    Table 28. Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 29. Therapeutics Major Business
    Table 30. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 31. Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 32. Therapeutics Recent Developments/Updates
    Table 33. Akcea Basic Information, Manufacturing Base and Competitors
    Table 34. Akcea Major Business
    Table 35. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 36. Akcea Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 37. Akcea Recent Developments/Updates
    Table 38. WAVElife Basic Information, Manufacturing Base and Competitors
    Table 39. WAVElife Major Business
    Table 40. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 41. WAVElife Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 42. WAVElife Recent Developments/Updates
    Table 43. ProQR Basic Information, Manufacturing Base and Competitors
    Table 44. ProQR Major Business
    Table 45. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 46. ProQR Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 47. ProQR Recent Developments/Updates
    Table 48. Exicure Basic Information, Manufacturing Base and Competitors
    Table 49. Exicure Major Business
    Table 50. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 51. Exicure Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 52. Exicure Recent Developments/Updates
    Table 53. Secarna Basic Information, Manufacturing Base and Competitors
    Table 54. Secarna Major Business
    Table 55. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 56. Secarna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 57. Secarna Recent Developments/Updates
    Table 58. AstraZeneca Basic Information, Manufacturing Base and Competitors
    Table 59. AstraZeneca Major Business
    Table 60. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 61. AstraZeneca Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 62. AstraZeneca Recent Developments/Updates
    Table 63. The WhiteOak Group, Inc. Basic Information, Manufacturing Base and Competitors
    Table 64. The WhiteOak Group, Inc. Major Business
    Table 65. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 66. The WhiteOak Group, Inc. Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 67. The WhiteOak Group, Inc. Recent Developments/Updates
    Table 68. Dicerna Basic Information, Manufacturing Base and Competitors
    Table 69. Dicerna Major Business
    Table 70. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 71. Dicerna Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 72. Dicerna Recent Developments/Updates
    Table 73. Silence Basic Information, Manufacturing Base and Competitors
    Table 74. Silence Major Business
    Table 75. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 76. Silence Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Silence Recent Developments/Updates
    Table 78. Arrowhead Basic Information, Manufacturing Base and Competitors
    Table 79. Arrowhead Major Business
    Table 80. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 81. Arrowhead Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 82. Arrowhead Recent Developments/Updates
    Table 83. Miragen Therapeutics Basic Information, Manufacturing Base and Competitors
    Table 84. Miragen Therapeutics Major Business
    Table 85. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 86. Miragen Therapeutics Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 87. Miragen Therapeutics Recent Developments/Updates
    Table 88. Genzyme Basic Information, Manufacturing Base and Competitors
    Table 89. Genzyme Major Business
    Table 90. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 91. Genzyme Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 92. Genzyme Recent Developments/Updates
    Table 93. Quark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 94. Quark Pharmaceuticals Major Business
    Table 95. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 96. Quark Pharmaceuticals Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 97. Quark Pharmaceuticals Recent Developments/Updates
    Table 98. Sylentis Basic Information, Manufacturing Base and Competitors
    Table 99. Sylentis Major Business
    Table 100. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 101. Sylentis Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 102. Sylentis Recent Developments/Updates
    Table 103. Avidity Biosciences Basic Information, Manufacturing Base and Competitors
    Table 104. Avidity Biosciences Major Business
    Table 105. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Product and Services
    Table 106. Avidity Biosciences Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. Avidity Biosciences Recent Developments/Updates
    Table 108. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Manufacturer (2018-2023) & (K Units)
    Table 109. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 110. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Manufacturer (2018-2023) & (US$/Unit)
    Table 111. Market Position of Manufacturers in Antisense oligonucleotides (ASO) Drug and siRNA Drug, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 112. Head Office and Antisense oligonucleotides (ASO) Drug and siRNA Drug Production Site of Key Manufacturer
    Table 113. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Company Product Type Footprint
    Table 114. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market: Company Product Application Footprint
    Table 115. Antisense oligonucleotides (ASO) Drug and siRNA Drug New Market Entrants and Barriers to Market Entry
    Table 116. Antisense oligonucleotides (ASO) Drug and siRNA Drug Mergers, Acquisition, Agreements, and Collaborations
    Table 117. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2018-2023) & (K Units)
    Table 118. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2024-2029) & (K Units)
    Table 119. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 120. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 121. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Region (2018-2023) & (US$/Unit)
    Table 122. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Region (2024-2029) & (US$/Unit)
    Table 123. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2023) & (K Units)
    Table 124. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2024-2029) & (K Units)
    Table 125. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 126. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 127. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Type (2018-2023) & (US$/Unit)
    Table 128. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Type (2024-2029) & (US$/Unit)
    Table 129. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2023) & (K Units)
    Table 130. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2024-2029) & (K Units)
    Table 131. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 132. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 133. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Application (2018-2023) & (US$/Unit)
    Table 134. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Application (2024-2029) & (US$/Unit)
    Table 135. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2023) & (K Units)
    Table 136. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2024-2029) & (K Units)
    Table 137. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2023) & (K Units)
    Table 138. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2024-2029) & (K Units)
    Table 139. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2023) & (K Units)
    Table 140. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2024-2029) & (K Units)
    Table 141. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 142. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 143. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2023) & (K Units)
    Table 144. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2024-2029) & (K Units)
    Table 145. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2023) & (K Units)
    Table 146. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2024-2029) & (K Units)
    Table 147. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2023) & (K Units)
    Table 148. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2024-2029) & (K Units)
    Table 149. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 150. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 151. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2023) & (K Units)
    Table 152. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2024-2029) & (K Units)
    Table 153. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2023) & (K Units)
    Table 154. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2024-2029) & (K Units)
    Table 155. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2018-2023) & (K Units)
    Table 156. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2024-2029) & (K Units)
    Table 157. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 158. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 159. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2023) & (K Units)
    Table 160. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2024-2029) & (K Units)
    Table 161. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2023) & (K Units)
    Table 162. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2024-2029) & (K Units)
    Table 163. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2018-2023) & (K Units)
    Table 164. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Country (2024-2029) & (K Units)
    Table 165. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 166. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 167. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2018-2023) & (K Units)
    Table 168. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Type (2024-2029) & (K Units)
    Table 169. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2018-2023) & (K Units)
    Table 170. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Application (2024-2029) & (K Units)
    Table 171. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2018-2023) & (K Units)
    Table 172. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity by Region (2024-2029) & (K Units)
    Table 173. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 174. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 175. Antisense oligonucleotides (ASO) Drug and siRNA Drug Raw Material
    Table 176. Key Manufacturers of Antisense oligonucleotides (ASO) Drug and siRNA Drug Raw Materials
    Table 177. Antisense oligonucleotides (ASO) Drug and siRNA Drug Typical Distributors
    Table 178. Antisense oligonucleotides (ASO) Drug and siRNA Drug Typical Customers
List of Figures
    Figure 1. Antisense oligonucleotides (ASO) Drug and siRNA Drug Picture
    Figure 2. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Type in 2022
    Figure 4. Antisense Oligonucleotides (ASO) Drug Examples
    Figure 5. siRNA Drug Examples
    Figure 6. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 7. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Application in 2022
    Figure 8. Single Gene Rare Disease Examples
    Figure 9. Protein Deposition Disease Examples
    Figure 10. Chronic Liver Disease Examples
    Figure 11. Others Examples
    Figure 12. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 13. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 14. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity (2018-2029) & (K Units)
    Figure 15. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price (2018-2029) & (US$/Unit)
    Figure 16. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Manufacturer in 2022
    Figure 17. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Manufacturer in 2022
    Figure 18. Producer Shipments of Antisense oligonucleotides (ASO) Drug and siRNA Drug by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 19. Top 3 Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturer (Consumption Value) Market Share in 2022
    Figure 20. Top 6 Antisense oligonucleotides (ASO) Drug and siRNA Drug Manufacturer (Consumption Value) Market Share in 2022
    Figure 21. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Region (2018-2029)
    Figure 22. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Region (2018-2029)
    Figure 23. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029) & (USD Million)
    Figure 24. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029) & (USD Million)
    Figure 25. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029) & (USD Million)
    Figure 26. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029) & (USD Million)
    Figure 27. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value (2018-2029) & (USD Million)
    Figure 28. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Type (2018-2029)
    Figure 29. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Type (2018-2029)
    Figure 30. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Type (2018-2029) & (US$/Unit)
    Figure 31. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Application (2018-2029)
    Figure 32. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Application (2018-2029)
    Figure 33. Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Average Price by Application (2018-2029) & (US$/Unit)
    Figure 34. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Type (2018-2029)
    Figure 35. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Application (2018-2029)
    Figure 36. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Country (2018-2029)
    Figure 37. North America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Country (2018-2029)
    Figure 38. United States Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 39. Canada Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 40. Mexico Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 41. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Type (2018-2029)
    Figure 42. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Application (2018-2029)
    Figure 43. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Country (2018-2029)
    Figure 44. Europe Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Country (2018-2029)
    Figure 45. Germany Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 46. France Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 47. United Kingdom Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 48. Russia Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. Italy Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 50. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Type (2018-2029)
    Figure 51. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Application (2018-2029)
    Figure 52. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Region (2018-2029)
    Figure 53. Asia-Pacific Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Region (2018-2029)
    Figure 54. China Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 55. Japan Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 56. Korea Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 57. India Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. Southeast Asia Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. Australia Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 60. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Type (2018-2029)
    Figure 61. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Application (2018-2029)
    Figure 62. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Country (2018-2029)
    Figure 63. South America Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Country (2018-2029)
    Figure 64. Brazil Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 65. Argentina Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 66. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Type (2018-2029)
    Figure 67. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Application (2018-2029)
    Figure 68. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Sales Quantity Market Share by Region (2018-2029)
    Figure 69. Middle East & Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value Market Share by Region (2018-2029)
    Figure 70. Turkey Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 71. Egypt Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 72. Saudi Arabia Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 73. South Africa Antisense oligonucleotides (ASO) Drug and siRNA Drug Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 74. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Drivers
    Figure 75. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Restraints
    Figure 76. Antisense oligonucleotides (ASO) Drug and siRNA Drug Market Trends
    Figure 77. Porters Five Forces Analysis
    Figure 78. Manufacturing Cost Structure Analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug in 2022
    Figure 79. Manufacturing Process Analysis of Antisense oligonucleotides (ASO) Drug and siRNA Drug
    Figure 80. Antisense oligonucleotides (ASO) Drug and siRNA Drug Industrial Chain
    Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 82. Direct Channel Pros & Cons
    Figure 83. Indirect Channel Pros & Cons
    Figure 84. Methodology
    Figure 85. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Alnylam
Ionis
Biogen
Novartis
Sarepta Therapeutics
Therapeutics
Akcea
WAVElife
ProQR
Exicure
Secarna
AstraZeneca
The WhiteOak Group, Inc.
Dicerna
Silence
Arrowhead
Miragen Therapeutics
Genzyme
Quark Pharmaceuticals
Sylentis
Avidity Biosciences

Related Reports

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Supply, Demand and Key Producers, 2023-2029

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Supply, Demand and Key Producers, 2023-2029

date 02 Sep 2023

date Pharma & Healthcare

The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 03 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Antisense oligonucleotides (ASO) Drug and siRNA Drug market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Supply, Demand and Key Producers, 2024-2030

Global Antisense oligonucleotides (ASO) Drug and siRNA Drug Supply, Demand and Key Producers, 2024-2030

date 10 Feb 2024

date Pharma & Healthcare

The global Antisense oligonucleotides (ASO) Drug and siRNA Drug market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

Product Tags

Antisense oligonucleotides (ASO) Drug and siRNA Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>